But as a historian of biology who has closely followed biomedicine in China over the past few years, I was less surprised by these developments.
News
- China's win-at-all-costs approach suggests it will follow its own dangerous path in biomedicine
- Tissue Regenix's Decellularized Human Dermis Product, DermaPure, Demonstrated Substantial ...
SAN ANTONIO--(BUSINESS WIRE)--Dec 17, 2018--Tissue Regenix Group ... INDUSTRY KEYWORD: STEM CELLS HEALTH BIOTECHNOLOGY ...
- Goodhaven Capital Management Has Decreased Federated Invs Pa (FII) Stake; Sellas Life ...
Sellas Life Sciences Group Inc (NASDAQ:SLS) had an increase of 12.66% in short interest. ... The SI to Sellas Life Sciences Group Inc's float is 14.47%. .... San Antonio Breast Cancer Symposium – Nasdaq” on November 30, 2018.
- Democrats Vow Rapid Action After Obamacare Thrown Out by Judge
Those include parts of the law on adding calorie counts on restaurant menus and speeding to market cheaper versions of costly biotechnology drugs.
- Dispensed: A secret patch, a $31 million pay package, and Amazon's ambitions in a $300 billion ...
Welcome to Dispensed, your weekly dose of the biotech, pharma, and healthcare stories that kept Business Insider's healthcare team busy this week.